Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial

BACKGROUND: Mazdutide (also known as IBI362 or LY3305677), a novel once-weekly glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist, achieved 12-week body weight loss up to 6.4% at doses up to 6 mg in Chinese adults with overweight or obesity. We further explored the safety and efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Linong, Gao, Leili, Jiang, Hongwei, Yang, Jing, Yu, Lei, Wen, Jie, Cai, Chenghang, Deng, Huan, Feng, Liqi, Song, Baili, Ma, Qingyang, Qian, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561728/
https://www.ncbi.nlm.nih.gov/pubmed/36247927
http://dx.doi.org/10.1016/j.eclinm.2022.101691

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561728/
https://www.ncbi.nlm.nih.gov/pubmed/36247927
http://dx.doi.org/10.1016/j.eclinm.2022.101691

Ejemplares similares